The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...

NEW YORK – The National Comprehensive Cancer Network has taken a more favorable stance on DPYD pharmacogenetic testing in recently updated colon, anal, rectal, and small bowel cancer treatment ...

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

The firm's artificial intelligence-based biomarker tools including Lunit Scope IO and Lunit Scope Universal IHC will be available across trials at the Center for Cancer Research.

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...